Pharmacokinetics of levobupivacaine for brachial plexus block in pediatric patients

Abstract

Abstract: AIM: To evaluate the clinical pharmacokinetics of levobupivacaine for brachial plexus block in pediatric patients. METHODS: 9 pediatric patients,undergoing elective upper shoulder surgery,were injected with levobupivacaine 0.375﹪(0.4 mL/kg)for interscalene brachial plexus block.The plasma concentration of levobupivacaine were determined at 10,20,30,45,60,90,120,180,240,360,480 and 840 min after injection,and the pharmacokinetic parameters were calculated with 3P97 software package. RESULTS: The plasma concentration-time curve was fitted to a two-compartment model,and the main pharmacokinetic parameter such as t_1/2β,t_max and C_max was (4.77±0.52),(0.28±0.14) h and (1.02±0.22) mg/L. CONCLUSION: Levobupivacaine 0.375% can be used for brachial plexus block in children safely,and its clinical pharmacokinetics is fitted to a two-compartment model.

Key words: Levobupivacaie, Brachial plexus block, Infant, Pharmacokinetics

CLC Number:

R969.1

TANG Xiao-li, WANG Cheng-hai, CUI Xiao-ning, SUN Kao-xiang, SHANG Shu-jun, SHAO Wei. Pharmacokinetics of levobupivacaine for brachial plexus block in pediatric patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1012-1015.

References

[1] 马民玉,王承海,冉菊红.患者硬膜外注射不同浓度左旋布比卡因的药代动力学[J].中华麻醉学杂志,2008,28(3):238-241.
[2] 王承海,唐晓莉,尚书军,等.肾上腺素对左旋布比卡因臂丛神经阻滞药代动力学的影响[J].中华麻醉学杂志,2010,30(6):767-768.
[3] 王承海,唐晓莉,尚书军,等.碱化左旋布比卡因肌间沟臂丛神经阻滞的药代动力学[J].国际麻醉学与复苏杂志,2011,32(1):18-20.
[4] Ohmura S,Kawada M,Ohta T,et al.Systemic toxicity and resuscitation in bupivacaine-,levobupivacaine-,or ropivacaine-infused rats[J].Anesth Analg,2001,93(3):743-748.
[5] Santos AC,De Armas PI.Systemic toxicity of levobupivacaine,bupivacaine,and ropivacaine during continuous intravenous infusion to nonpregnant and pregnant ewes[J].Anesthesiology,2001,95(5):1256-1264.
[6] Casati A,Santorsola R,Aldegheri G,et al.Intraoperative epidural anesthesia and postoperative analgesia with levobupivacaine for major orthopedic surgery:a double-blind,randomized comparison of racemic bupivacaine and ropivacaine[J].J Clin Anesth,2003,15(2):126-131.
[7] Breschan C,Jost R,Krumpholz R,et al.A prospective study comparing the analgesic efficacy of levobupivacaine,ropivacaine and bupivacaine in pediatric patients undergoing caudal blockade[J].Pediatric Anesthesia,2005,15(4):301-306.
[8] Chalkiadis GA,Eyres RL,Cranswick N.Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age[J].Br J Anaesth,2004,92(2):218-222.
[9] Chalkiadis GA,Anderson BJ.Age and size are the major covariates for prediction of levobupivacaine clearance in children[J].Paediatr Anaesth,2006,16(3):275-282.
[10] Kopacz DJ, Allen HW. Accidental intravenous levo-bupivacaine[J]. Anesth Analg,1999,89(4):1027.
[11] Salomaki TE,Laurila PA,Ville J.Successful resuscitation after cardiovascular collapse following accidental intravenous infusion of levobupivacaine during general anesthesia [J]. Anesthesiology,2005,103(5):1095-1096.
[12] Gristwood RW,Greaves JL.Levobupivacaine:a new safer long acting local anaesthetic agent[J].Exper Opin Invest Drug,1999,8(6):861-876.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.